Squarepoint Ops LLC - 09 Mar 2026 SCHEDULE 13G Report for Cartesian Therapeutics, Inc. Common Stock (RNAC)

Filing Manager
Squarepoint Ops LLC
Reporting Manager
Squarepoint Ops LLC
Security
Cartesian Therapeutics, Inc. Common Stock
Symbol
RNAC
Shares outstanding
26,621,699 shares
Disclosed Ownership
2,209,601 shares
Ownership
8.3%
Form type
SCHEDULE 13G
Filing time
13 Mar 2026, 15:55:02 UTC
Date of event
09 Mar 2026
SEC
View on sec.gov

Quoteable Key Fact

"Squarepoint Ops LLC disclosed 8.3% ownership in Cartesian Therapeutics, Inc. Common Stock (RNAC) on 09 Mar 2026."

Quick Takeaways

  • Squarepoint Ops LLC filed SCHEDULE 13G for Cartesian Therapeutics, Inc. Common Stock (RNAC).
  • Disclosed ownership: 8.3%.
  • Date of event: 09 Mar 2026.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Mar 2026, 15:55.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Squarepoint Ops LLC 8.3% 2,209,601 0 2,209,601 /s/ John Weitzer Chief Compliance Officer
Squarepoint Capital LLP 8.3% 2,209,601 0 2,209,601 /s/ John Weitzer Chief Compliance Officer
Squarepoint Operations Private Limited 8.3% 2,209,601 0 2,209,601 /s/ John Weitzer Chief Compliance Officer
Squarepoint (DIFC) Ltd 8.3% 2,209,601 0 2,209,601 /s/ John Weitzer Chief Compliance Officer
Squarepoint Master Fund Limited 8.2% 2,178,652 0 2,178,652 /s/ John Weitzer Chief Compliance Officer
Squarepoint Core Master Fund Limited 0.1% 30,949 0 30,949 /s/ John Weitzer Chief Compliance Officer
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .